Allero Therapeutics Expands Management Team with Two Key Hires
Ghent, Belgium / Rotterdam, The Netherlands – December 15, 2020
Allero Therapeutics BV, a Belgian-Dutch oromucosal immunotherapy company, today announced the appointment of two key members to its management team.
As of December 1, 2020, Steven Glazer has joined the Company as Chief Medical Officer and Christophe Saillez as Vice President Regulatory Affairs.
Steven Glazer, MD, PhD, brings more than 25 years of senior management experience, including roles as CMO of Monta Bioscience, Idogen, RhoVac and senior R&D positions at Novo Nordisk, Maxygen and BioInvent. In addition, he is a Board Member and Chairman of the Scientific Committee at Immunicum and a Partner at the life science consulting firm Ventac Partners. Steven Glazer has extensive knowledge of drug development, medical and regulatory affairs in pharmaceutical, biopharmaceutical, biotechnology and diagnostic companies in Europe and the United States.
Christophe Saillez is a regulatory and scientific expert with over 20 years experience in global regulatory aspects, CMC, quality assurance and validation, with in-depth knowledge and practice regarding the requirements from regulatory agencies. He held management roles at pharma and biotech companies such as GSK, Actobio Therapeutics, and Janssen Vaccines. He is a biochemical engineer by training.
“We are excited that Steven and Christophe will strengthen our management team and bring significant clinical and regulatory expertise to Allero,” said Emil Pot, CEO of Allero Therapeutics. “Their strong track record will be very beneficial in advancing our proprietary Specific OroMucosal ImmunoTherapy (SOMIT) technology platform, which is leveraging the unique properties of the oral immune system. We believe that we are now very well positioned to further mature our product pipeline in allergic and autoimmune diseases as well as our COVID-19 program in collaboration with Abbreos.”
Dr. Ludger Wess / Ines-Regina Buth
Tel. +49 40 88 16 59 64 /
Tel. +49 30 23 63 27 68
About Allero Therapeutics
Allero Therapeutics was founded in November 2016 and seed-financed in 2019 by Curie Capital and Swanbridge Capital. Allero Therapeutics is an immunotherapy company building a portfolio of first-in-class programs based on its proprietary Specific OroMucosal ImmunoTherapy (SOMIT) technology platform. The company is developing a pipeline of products in the field of food-related immune disorders such as Celiac Disease and food allergies, which currently affect 10% of the population worldwide - with rising tendency. While there is no cure other than avoidance of particular food ingredients, patients and families are experiencing a significant impact on their quality of life. More info: http://www.allerotherapeutics.com/